Our research aims to improve the efficacy of standard of care immunotherapy, chemotherapy and radiotherapy in human solid cancers by understanding the molecular mechanisms underlying tumour stromal contributions to tumour growth and therapy efficacy.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted.
We are interested in how cancer cells interact with each other and the microenvironment. We investigate how cancer cell communication with neighbouring stromal cells and the extracellular matrix can impact on invasion and response to targeted therapies, to try to block cancer progression, with a particular focus on breast and pancreatic cancer.
Our group focuses on understanding the molecular and cellular mechanisms that mediate resistance to anti-cancer therapies in breast cancer. We are interested in dissecting the microenvironmental cues that orchestrate specific tumour responses and metastasis formation.
Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time such as Adaptive Therapy.
My research focuses on novel strategies to enrich, isolate and characterise a chemo-resistant population in patients with follicular lymphoma.
My research is focused on the role of lipid metabolism in resistance to therapy in acute myeloid leukemia.
My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.
My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.
My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.